Clinical Trial Update: Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 bioequivalence and food-effect study of bosutinib in healthy subjects to support its use in Philadelphia chromosome-positive chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BOSULIF (bosutinib)

Snippet

Sponsor: Pfizer | Conditions: Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML) | Phase 1 | Status: COMPLETED